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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
19.11.2020 Antibodies to 
SARS-CoV-2 
are 
associated 
with 
protection 
against 
reinfection 
medRxiv | 
pre-print (not 
peer-
reviewed) 
• Investigation of 
incidence of SARS-CoV-
2 PCR-positive results in 
seropositive and 
seronegative 12,219 
healthcare workers 
attending asymptomatic 
and symptomatic staff 
testing at Oxford 
University Hospitals, UK 
• Prior SARS-CoV-2 
infection that generated 
antibody responses 
offered protection from 
reinfection for most 
people in the six months 
following infection 
• Further work required to 
determine longer-term 
protection and correlates 
of post-infection 
immunity 
Antibody 
protection 
Oct 2020 Establishment 
of a high-
dependency 
unit in Malawi 
BMJ Global 
Health 
|Practice 
• Description of a 
participatory approach to 
design and implement a 
sustainable high-
dependency unit for low-
income SSA setting 
(tertiary referral centre 
Participatory 
approach, 
high-
decency 
unit 
serving Malawi’s 
Southern region) 
• This included: 
prospective agreement 
on remit, alignment with 
existing services, 
refurbishment of a 
dedicated physical 
space, recruitment and 
training of specialist 
nurses, development of 
context-sensitive clinical 
standard operating 
procedures, purchase of 
appropriate and durable 
equipment and creation 
of digital clinical 
information systems 
• Description includes 
acceleration of the 
opening of the unit and 
how it responded to the 
COVID-19 demand 
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
19.11.2020 SARS-CoV-2, 
SARS-CoV, 
and MERS-
CoV viral load 
dynamics, 
duration of 
viral shedding, 
and 
infectiousness: 
a systematic 
review and 
meta-analysis  
The Lancet 
Microbe | 
Systematic 
Review and 
meta-analysis 
• SR and MA of viral load 
kinetics and duration of 
viral shedding in various 
body fluids, important 
determinants for disease 
transmission 
• Although SARS-coV-2 
RNA shedding in 
respiratory and stools 
samples can be 
prolonged, duration of 
viable infectious virus is 
relatively short-lived 
• SARS-CoV-2 titres in the 
upper respiratory tract 
peak in the first week of 
illness 
• Early case finding and 
isolation, public education 
on the spectrum of illness 
and period of 
infectiousness are key to 
containing spread well 
infectiousness 
Infection Prevention and Control 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
20.11.2020 Physical 
interventions 
to interrupt 
or reduce 
the spread 
of 
respiratory 
viruses 
Cochrane | 
Systematic 
Review 
• This updated SR 
assessed the 
effectiveness of physical 
interventions to interrupt 
or reduce the spread of 
acute respiratory viruses 
• Note does not include 
results from studies from 
the current COVID-19 
pandemic 
• The high risk bias in the 
trials variation in outcome 
measurement, and 
relatively low compliance 
with the interventions 
during the studies prevent 
firm conclusions being 
drawn and generalising 
findings to the COVID-19 
pandemic  
• Authors state that there is 
a need for large, well-
designed RCTs 
addressing effectiveness 
of many of these 
interventions in multiple 
settings and populations 
and especially in those 
most at risk of acute 
respiratory infections 
Physical 
interventions 
Testing 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
19.11.2020 Routine 
laboratory 
testing to 
determine 
if a 
patient 
has 
Cochrane | 
Systematic 
Review 
• Specific diagnostic tests to detect 
SARS-CoV-2 and resulting 
disease are not always available 
and take time to obtain results 
• This SR assesses the diagnostic 
accuracy of routine laboratory 
testing as a triage test to 
determine if a person has 
COVID-19 
 Triage, 
routine 
laboratory 
testing 
COVID-
19  
• None of the tests investigated are 
useful for accurately ruling in or 
out COVID-19 on their own 
• Studies done were in specific 
hospitalised populations and 
future studies could consider 
evaluation of these tests in non-
hospital settings to see how 
these tests would perform in 
people with milder symptoms  
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
18.11.2020 Safety and 
immunogenicity 
of ChAdOx1 
nCoV-19 
vaccine 
administered in 
a prime-boost 
regimen in 
young and old 
adults 
(COV002) a 
single-blind, 
randomised, 
controlled, 
phase 2/3 trial  
The Lancet | 
Article 
• Older adults (aged 
>=70y) are at 
increased risk of 
severe disease and 
death if they 
develop COVID-19 
symptoms and are 
therefore a priority 
for an effective 
COVID-19 vaccine 
but immunogenicity 
of vaccines is often 
worse in older 
adults as a result of 
immunosenescence 
• Safety and 
immunogenicity of 
ChAdOx1 nCoV-19 
in a phase 2 
component of a 
single-blind, 
randomised, 
controlled, phase 
2/3 trial (COV002) 
in healthy adults 
enrolled in an age-
escalation manner 
(18-55y, 56-69y 
and 70years plus) 
at two UK sites - a 
wider range of 
participants than 
previously reported 
• Results show that 
ChAdOx1 nCoV-19 
appears to be 
better tolerated in 
Oxford vaccine, 
safety, 
immunogenicity, 
older adults 
older adults than in 
younger adults and 
has similar 
immunogenicity 
across all age 
groups after a boost 
dose 
17.11.2020 Safety, 
tolerability, and 
immunogenicity 
of an 
inactivated 
SARS-CoV-2 
vaccine in 
healthy adults 
aged 18-59 
years: a 
randomised, 
double-blind, 
placebo-
controlled, 
phase1/2 
clinical trial 
The Lancet 
Infectious 
Diseases | 
Article 
• Randomised, 
double-blind, 
placebo controlled, 
phase1/2 clinical 
trial, in healthy 
adults in China of 
an inactivated 
vaccine candidate 
CoronaVac 
(Sinovac Life 
Sciences)  to 
screen safety of two 
doses and two 
vaccination 
schedules in a 
small cohort before 
expanding to a 
larger cohort to 
explore 
immunogenicity 
• Data on safety, 
immunogenicity, 
and production 
capacity support 
assessment of the 
3ug dose of 
CoronaVac in 
phase 3 clinical 
trials already 
ongoing in Brazil, 
Indonesia and 
Turkey 
CoronaVac, 
safety, 
tolerability, 
immunogenicity 
   
• Refer to 
Comments, 
Editorials, Opinions, 
Blogs, News 
Section below for 
press releases on 
vaccine candidates 
 
Social Science 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
2020 Vaccine 
Hesitancy and 
Building 
Confidence in 
COVID-19 
Vaccination 
SSHAP | 
Rapid Review 
• Drawing on social science 
literature and informal 
interviews with experts, 
this brief highlights the 
complexity of and context-
specific reasons for 
vaccine hesitancy 
reflecting not just 
exposure to 
misinformation or anti-
vaccine campaigners but 
also diverse, everyday 
anxieties 
• Strategies are proposed 
to guide policy makers, 
public health officials, 
vaccine developers, 
health workers, 
researchers, advocates, 
communicators, media 
actors and other involved 
in vaccine development, 
communication and 
deployment to increase 
confidence in COVID-19 
vaccines 
• This brief is part of a 
series on vaccines 
Vaccine 
hesitancy 
2020 Risk 
Communications 
and Community 
Engagement to 
Overcome 
COVID-19 
Fatigue in 
Eastern 
Mediterranean, 
Middle East and 
North Africa 
SSHAP | 
Evidence 
Review 
• A focus on social and 
cultural influences for 
sustained COVID-19 
prevention and risk 
reduction behaviours in 
the MENA region to 
overcome fatigue or 
complacency about 
measures designed to 
protect 
• A brief synthesis of 
UNICEF’s comprehensive 
review of the evidence to 
inform the development of 
risk communication and 
community engagement 
strategies and regional 
RCCE, 
MENA 
guidance and tools as the 
COVID-19 crisis evolves 
• Operational 
considerations based on 
the findings are given 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type 
23.11.2020 Oxford University breakthrough on global 
COVID-19 vaccine 
University of Oxford | News 
23.11.2020 Launching an interactive webtool to analyse the 
COVID-19 vaccine portfolio  
CGD | Blog 
22.11.2020 COVID-19 vaccine predictions: the interactive 
tool 
CGD | Tool 
21.11.2020 FDA authorizes monoclonal antibodies for 
treatment of COVID-19 
FDA | News 
20.11.2020 Policy makers must act on incomplete evidence 
in responding to COVID-19 
Cochrane | Editorial 
20.11.2020 Ethical and scientific considerations regarding 
the early approval and deployment of a COVID-
19 vaccine 
Annals Internal Medicine | 
Ideas and Opinions 
20.11.2020 Pfizer and BioNTech to submit emergency use 
authorization request today to the U.S. FDA for 
COVID-19 vaccine 
Pfizer | News 
20.11.2020 WHO Guideline Development Groups advises 
against use of remdesivir for COVID-19 
BMJ | News 
20.11.2020 Lessons from around the world on fighting 
COVID’s second wave  
The Conversation | Jimmy 
Whitworth 
20.11.2020 Strengthening pandemic preparedness and 
response begins with answering the question: 
where are the women? 
BMJ | Opinion 
19.11.2020 Tocilizumab treatment in critically ill COVID-19 
patients 
@rempa_cap | Twitter thread  
18.11.2020 Age and frailty in COVID-19 vaccine 
development  
The Lancet | Comment 
18.11.2020 Ensuring access to essential sexual and 
reproductive health products during COVID-19: 
challenges and future directions 
Health Policy and Planning 
Debated | Blog 
18.11.2020 The syndemic of COVID-19 and gender-based 
violence in humanitarian settings: leveraging 
lessons from Ebola in the Democratic Republic 
of Congo 
BMJ Global Health | 
Commentary 
18.11.2020 A platform to support the researchers and 
decision-makers generating and using health 
economics research to tackle COVID-19 
CGD | Blog 
18.11.2020 A proposed framework and timeline of the 
spectrum of disease due to SARS-CoV-2 
infection 
JAMA | Viewpoint 
17.11.2020 A look inside laboratories responding to 
COVID-19  
WHO | Blog 
16.11.2020 India’s syndemic of tuberculosis and COVID-19 BMJ Global Health | Editorial 
 
  
Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 
20.11.2020 Therapeutics and 
COVID-19: living 
guideline 
WHO | 
Guideline 
• Update to a living guideline on 
clinical care for COVID-19 with a 
conditional recommendation 
against the use of remdesivir in 
hospitalised patients, regardless of 
disease severity, as there is no 
evidence that remdesivir improves 
survival and other outcomes in 
these patients 
04.11.2020 Considerations for 
implementing and 
adjusting public 
health and social 
measures in the 
context of COVID-
19 
WHO | 
Interim 
guidance 
• Update to 16 April interim guidance 
on public health social measures, 
including non-pharmaceutical 
individual and societal 
interventions to control COVID-19 
 
   
 
Dashboards & Trackers 
Cases & deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living evidence & 
policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  
Indonesia  EPPI Centre  WHO International 
Clinical Trials 
Registry Platform 
(ICTRP)  
 FIND SARS-
CoV-2 
Diagnostics: 
performance 
data 
  US NIH 
registered 
clinical trials 
Vaccine 
Centre 
LSHTM  
Johns Hopkins 
University  
European 
CDC  
Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 
WEF    Sierra Leone   Oxford C19 
Government 
Response 
Tracker 
(OxCGRT) 
US NIH   Our World in 
Data: C19 
Testing 
  COVID-19 
Therapeutics 
Accelerator 
 COVID-19 
Vaccine 
Tracker 
Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence        
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
  
   
 
C19 Resource Hubs 
Global  Regional 
& Country 
Academi
c 
journals 
& 
Publisher
s 
Institutes/Centres/Funders/
Other 
Health 
Topics 
  Social 
Sciences 
WHO 
COVID-19 
pandemic  
Africa 
CDC 
Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communicati
on 
African 
Union 
BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin 
of the 
WHO 
ICL MRC Centre for Global 
Infectious Disease Analysis  
Global 
Menstrual 
Collective  
  Disability 
and 
inclusion 
WHO Global 
research 
GeoPoll: 
SSA 
Cambrid
ge 
Universit
y Press 
ODI SLH: 
Handwashi
ng in low 
resource 
settings 
  Coregrou
p IDDC 
COVID-19 
Solidarity 
Response 
Fund 
Global 
Health 
Network 
Africa 
Cell 
Press 
Johns Hopkins University RBM 
Partnership 
  Ethics, 
health 
systems & 
COVID-19 
UN African 
Academy 
of 
Sciences 
Cochran
e  
Center for Global 
Development 
 Epidemic 
Preparedne
ss 
Innovations 
  Social 
Developm
ent Direct 
C19 blog 
series 
UN Women Africa 
Evidence 
Network 
Elsevier CMMID Repository     
UNOCHA OCHA 
Southern 
and 
Eastern 
Africa 
COVID-19 
Digest 
Health 
Policy 
and 
Planning  
Norwegian Institute of 
Public Health 
    
UNHCR  South 
African 
Governme
nt 
JAMA 
Network 
Oxford Centre for 
Evidence-based Medicine 
    
UNICEF   The 
Lancet 
 HEART     
UNESCO   medRxiv 
and 
bioRxiv 
(Preprint
s) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
Universit
y Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources and 
Analyses of C19 Impact 
    
World Bank   SAGE 
journals 
 Prevent Epidemics      
Our World in 
Data 
  Science       
COVID-19 
Narratives by 
David 
Nabarro 
  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprint
s)  
      
Humanitarian 
OpenStreetM
ap Team 
  Wiley       
Global 
Partnership 
for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global 
Impact Study 
    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
04.12.2020 COVID-19, supply 
chain resilience and 
global trade 
Webinar 1h CGD 
03.12.2020 More money for 
health services: What 
WHO & CGD 
Health systems 
1h 30 Joe Kutzin 
is the tole of PFM in 
the “new normal”? 
Governance & 
Financing 
19.11.2020 Looking at the 
pandemic with a 
gender lens 
Live Twitter 
conversation 
  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 
expertise around the 
maintenance of 
essential health 
services during (and 
after) the pandemic 
4-week 
discussion 
starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 
Online courses Varies WHO 
Available 
now 
Standard 
precautions: 
Environmental 
cleaning and 
disinfection 
Online course 1 hour WHO 
Available 
now 
COVID-19: Effective 
Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 
Johns Hopkins School 
of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, 
Modelling and Policy 
Online learning 2 weeks | 
2 hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays 
at 1700 
CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
Online learning 3 hours WHO 
prevention, response 
and control 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online learning Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel 
Coronavirus 
Online learning 3 weeks | 
4 hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online learning 3 weeks | 
3 hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online learning 5 weeks | 
1 hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online learning Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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